The ASIST study will assess the safety and efficacy of BXQ-350 plus SOC, modified FOLFOX7 (mFOLFOX7) and bevacizumab, in patients with newly diagnosed mCRC. The study is also evaluating whether the ...
JonesTrading analyst Debanjana Chatterjee has reiterated their bullish stance on NTLA stock, giving a Buy rating on November 13. Debanjana ...
Leading the Way in Specialized Diabetic Foot Care in Delhi NCRDelhi, India - November 17, 2024 — Diabetes, often called the ...